The Centers for Disease Control and Prevention beneficial on Tuesday {that a} newly licensed vaccine from Novavax be used as an choice for adults in search of a major immunization towards the coronavirus.

Dr. Rochelle Walensky, the C.D.C.’s director, signed off on the advice of a panel of vaccine consultants that had unanimously endorsed the vaccine on Tuesday afternoon. The determination removes the ultimate regulatory hurdle for the fourth Covid-19 shot licensed within the United States.

The Novavax vaccine is predicted to play a restricted function within the nation’s immunization marketing campaign, at the least initially. The Food and Drug Administration licensed it final week as a major immunization for adults, however has not but thought of it for a booster shot.

Novavax, a Maryland pharmaceutical firm, obtained vital federal funding to develop its shot however fell far behind within the vaccine race. Even so, it’s hoping the shot will enchantment to Americans who’ve thus far declined to be vaccinated.

Somewhere between 26 and 37 million adults within the United States haven’t but obtained a coronavirus vaccine, in line with survey knowledge introduced on the assembly by Dr. Katherine Fleming-Dutra of the C.D.C.

But within the international locations the place it has been obtainable for months, Novavax’s shot has but to have a big impact on vaccination charges. Novavax stated in its presentation to the panel on Tuesday that simply over one million doses of its vaccine had been administered worldwide by means of the top of June, a tiny quantity in contrast with the attain of competing photographs.

The Biden administration stated final week that it might purchase 3.2 million doses of Novavax’s two-shot vaccine, sufficient to completely vaccinate 1.6 million folks within the United States. The vaccine isn’t but obtainable in pharmacies and different clinics that administer photographs. Novavax stated in a information launch after the vote that the F.D.A. had signed off on the primary doses supposed for the United States and that the corporate anticipated to ship its vaccine to a distribution middle “in the coming days.”

With two doses spaced three weeks aside, the vaccine was discovered to be extremely protecting towards an infection and extreme illness from the coronavirus in medical trials. But these have been carried out earlier than the emergence of the Omicron variant, which has sharply lowered the effectiveness of different licensed vaccines in stopping infections.

Novavax’s vaccine works otherwise from the three Covid vaccines beforehand licensed within the United States. It provokes an immune response with nanoparticles made up of proteins from the floor of the coronavirus that causes Covid-19. Similar protein-based vaccines have been used globally for many years.

Dr. Evelyn Twentyman of the C.D.C. introduced outcomes from a survey suggesting that comparatively few unvaccinated Americans would select Novavax. Just 16 % of unvaccinated respondents stated they “probably” or “definitely” would get a protein-based Covid vaccine, and 50 % of unvaccinated respondents stated they “probably” or “definitely” wouldn’t.

At the assembly on Tuesday, C.D.C. officers reviewed medical trial knowledge that has linked the vaccine to an elevated however small danger of creating types of coronary heart irritation often called myocarditis and pericarditis.

Dr. Filip Dubovsky, the chief medical officer at Novavax, stated on the assembly that the corporate had been monitoring instances of coronary heart irritation in international locations the place the vaccine was already licensed. Surveying simply over one million doses, the corporate has recognized 17 particular or possible instances of myocarditis and pericarditis, he stated.